Text Size

The Influence of a Bupivacaine Digital Nerve Block Using Rev G.

This study is currently recruiting participants.
Verified May 2013 by University of California, San Francisco
Sponsor:
Information provided by (Responsible Party):
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT01750554
First received: December 10, 2012
Last updated: May 31, 2013
Last verified: May 2013
History of Changes
  Purpose

The investigators are proposing to continue investigation to improve the accuracy of the SpHb (continuous hemoglobin monitoring device) by administering an intermediate acting digital nerve block in the finger connected to the SpHb, specifically bupivacaine 0.25% in patients undergoing spine surgery. Bupivacaine is FDA approved and in routine use.


Condition Intervention Phase
Patients Undergoing Spine Surgery
 Drug: Bupivacaine
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Influence of a Bupivacaine Digital Nerve Block With the New Continuous Sensor (Rev G) on the Accuracy of SpHb Monitoring.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • SpHb (continuous hemoglobin monitor reading) minus tHb (clinical laboratory determined hemoglobin value). [ Time Frame: Intermittent (about hourly) hemoglobin checks throughout the surgery. ] [ Designated as safety issue: No ]

    Use of a longer acting local anesthetic (bupivacaine) for the digital nerve block will result in SpHb (the non-invasive hemoglobin device) being sufficiently accurate for blood transfusion decisions(≤ 1.0 g/dL difference)

    To assess if using an intermediate-acting digital nerve block will improve the accuracy of the SpHb readings when compared to a blood hemoglobin level analyzed in the UCSF Clinical Laboratories intermittently during the patient's surgery.



Estimated Enrollment: 25
Study Start Date: December 2012
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: bupivacaine digital nerve block
Patients undergoing spine surgery will have a 50/50 chance of being randomized to receive a bupivacaine 0.25% (2 milliliters total) digital nerve block.
 Drug: Bupivacaine
No Intervention: No bupivacaine digital nerve block
Patients undergoing spine surgery will have a 50/50 chance of being randomized to not receive a bupivacaine 0.25% (2 milliliters total) digital nerve block.

Detailed Description:

Patients undergoing spine surgery will be randomized to receive (or not) the bupivacaine digital block on the finger attached to the new limited release version of the hemoglobin sensor, RevG. The SpHb reading will be compared to a blood hemoglobin level analyzed in the UCSF Clinical Laboratories.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female 18 years of age or older
  • American Society of Anesthesiologists classification 1, 2 or 3
  • Scheduled to undergo spine or hip surgery

Exclusion Criteria:

  • Pregnant or nursing
  • Patients who in the study investigators clinical judgement would not be suitable
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01750554

Contacts
Contact: Ronald D Miller, MD, MS (415) 476-9034 millerr@anesthesia.ucsf.edu
Contact: Theresa A Ward, BSN, RN (415) 514-0685 wardt@anesthesia.ucsf.edu

Locations
United States, California
University of California, San Francisco Recruiting
San Francisco, California, United States, 94143
Contact: Ronald D Miller, MD, MS     415-476-9034     millerr@anesthesia.ucsf.edu    
Contact: Theresa A Ward, BSN, RN     (415) 514-0685     wardt@anesthesia.ucsf.edu    
Principal Investigator: Ronald D Miller, MD, MS            
Sponsors and Collaborators
University of California, San Francisco
Investigators
Principal Investigator: Ronald D Miller, MD, MS University of California, San Francisco
  More Information

No publications provided

Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT01750554     History of Changes
Other Study ID Numbers: 10-00524D
Study First Received: December 10, 2012
Last Updated: May 31, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, San Francisco:
SpHb; hemoglobin monitoring;bupivacaine digital nerve block

Additional relevant MeSH terms:
Bupivacaine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
 Pharmacologic Actions
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on June 17, 2013